> **来源：[研报客](https://pc.yanbaoke.cn)** ```markdown # Jupiter Neurosciences, Inc. - Summary of Registration Statement (Form S-1) ## Core Information - **Company Name**: Jupiter Neurosciences, Inc. - **Jurisdiction of Incorporation**: Delaware - **I.R.S. Employer Identification Number**: 47-4828381 - **Principal Executive Office**: 11621 Kew Gardens Avenue, Suite 210, Palm Beach Gardens, Florida 33410 - **Telephone Number**: (561) 406-6154 - **Selling Stockholder**: YA II PN, LTD (Yorkville) - **Shares Being Registered**: Up to 16,000,000 shares of common stock - **Nasdaq Listing**: Under the symbol "JUNS", with a closing price of \$2370 on June 25, 2026 - **Registration Statement**: Previously effective on December 11, 2025 (Form S-1, 333-291832) - **Previously Sold Shares**: 5,815,975 shares for \$2.8 million ## Main Purpose of the Registration Statement This registration statement is part of a broader offering to register the resale of up to 16,000,000 shares of common stock by Yorkville. The Company is not selling any shares directly and will not receive proceeds from the sale of shares by the Selling Stockholder. However, the Company may receive additional proceeds from future sales to Yorkville under the Standby Equity Purchase Agreement (SEPA). ## Key Information and Highlights ### Company Overview - **Location**: Jupiter, Florida - **Business Focus**: Clinical stage pharmaceutical company with a focus on CNS disorders and rare diseases, and expansion into the consumer market with the Nugevia™ product line. - **Technology**: JOTROL™, a proprietary enhanced resveratrol formulation that shows improved bioavailability in FDA-regulated Phase I studies. - **Product Line**: Nugevia™, a consumer-oriented line of nutritional products designed to support longevity and wellness, with three debut formulations: GLO, MND, and PWR. ### Clinical Development - **Parkinson’s Disease**: Completed preclinical studies in 2021 and initiated a Phase IIa clinical trial in November 2025, expected to start in Q2 2026 and report results in 12 months. - **Other CNS Indications**: Plans to investigate Mild Cognitive Impairment (MCI) and Alzheimer’s disease following the Parkinson’s study. - **Resveratrol Bioavailability**: Studies suggest that for therapeutic effects, resveratrol levels in blood plasma should reach \$300\mathrm{ng / ml}\$ or higher. JOTROL™ has demonstrated levels exceeding \$800\mathrm{ng / ml}\$ without severe adverse events. ### Market and Business Strategy - **Nugevia™ Market**: Targets a global industry expected to reach \$8 trillion by 2030. - **Asia Focus**: Gained significant interest from Asian organizations due to resveratrol's traditional use, recent patent approvals, and applicability to rare diseases in China. - **Partnerships**: Entered into service agreements with firms in Hong Kong and an agreement with Dominant Treasure Health to expand into China, Malaysia, and Singapore. ### Financial and Legal Context - **SEPA and Registration Rights Agreement**: Signed on October 24, 2025, with Yorkville. The Company may receive up to \$17.2 million in gross proceeds from future sales to Yorkville. - **Previous Sales**: 5,815,975 shares sold for \$2.8 million under the Prior Registration Statement. - **Legal Matters**: Legal and accounting fees related to the registration of the shares are to be paid by the Company. ### Risk Factors - **Substantial Indebtedness**: Convertible promissory notes may affect cash flow and compliance. - **Low Trading Volume**: May limit the ability to draw on the SEPA to pay down debt. - **Operating Losses**: The Company has incurred significant net losses and may continue to do so. - **Going Concern Uncertainty**: Management and auditors have raised concerns about the Company’s ability to continue operations. - **Capital Needs**: Substantial additional capital is required to fund operations and development. - **Competition**: Rapid development by competitors could negatively impact commercial opportunities. - **Regulatory Challenges**: Possible rejection of data from foreign trials and changes in regulations. - **Talent Retention**: Success is highly dependent on attracting and retaining skilled personnel. - **Listing Risks**: Failure to meet Nasdaq requirements could lead to delisting. - **Stock Volatility**: High volatility due to small capitalization and public float, with potential for short squeezes and price fluctuations. - **Global Market Disruptions**: Effects of geopolitical conflicts (Russia-Ukraine, Middle East) on credit and financial markets. ## Summary of the Offering - **Type of Offering**: Resale of up to 16,000,000 shares of common stock. - **Selling Stockholder**: Yorkville, an underwriter under the Securities Act. - **Proceeds to the Company**: Up to \$17.2 million from future sales under the SEPA. - **Plan of Distribution**: Detailed in the prospectus, outlining various methods Yorkville may use to sell the shares. - **Forward-Looking Statements**: The prospectus contains forward-looking statements subject to risks and uncertainties, including those related to clinical trials, regulatory approvals, and market conditions. ## Conclusion The registration statement outlines the Company's efforts in pharmaceutical and consumer product development, leveraging its proprietary JOTROL™ technology. It also details the SEPA with Yorkville, which allows for the resale of up to 16 million shares of common stock. The Company faces significant risks, including financial, regulatory, and competitive challenges, and is reliant on future capital raises and the success of its clinical trials. The Nugevia™ product line represents a strategic move to enter the wellness market and monetize its scientific research. ```